SG158096A1 - Dosage regimen of an s1p receptor agonist - Google Patents

Dosage regimen of an s1p receptor agonist

Info

Publication number
SG158096A1
SG158096A1 SG200907947-6A SG2009079476A SG158096A1 SG 158096 A1 SG158096 A1 SG 158096A1 SG 2009079476 A SG2009079476 A SG 2009079476A SG 158096 A1 SG158096 A1 SG 158096A1
Authority
SG
Singapore
Prior art keywords
daily dosage
receptor agonist
dosage regimen
dosage
standard
Prior art date
Application number
SG200907947-6A
Other languages
English (en)
Inventor
John M Kovarik
Silke Appel-Dingemanse
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG158096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG158096A1 publication Critical patent/SG158096A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
SG200907947-6A 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist SG158096A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29

Publications (1)

Publication Number Publication Date
SG158096A1 true SG158096A1 (en) 2010-01-29

Family

ID=36046868

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200907947-6A SG158096A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist
SG2013002662A SG187468A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013002662A SG187468A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Country Status (21)

Country Link
US (3) US20090275553A1 (enExample)
EP (3) EP1819326B1 (enExample)
JP (4) JP2008521827A (enExample)
KR (4) KR20130041385A (enExample)
CN (2) CN101068536B (enExample)
AU (1) AU2005309378B2 (enExample)
BR (1) BRPI0518674A2 (enExample)
CA (1) CA2589265A1 (enExample)
ES (1) ES2495690T3 (enExample)
IL (2) IL183134A0 (enExample)
MA (1) MA29034B1 (enExample)
MX (1) MX2007006373A (enExample)
NO (2) NO20072401L (enExample)
NZ (2) NZ554720A (enExample)
PL (1) PL1819326T3 (enExample)
PT (1) PT1819326E (enExample)
RU (2) RU2478384C2 (enExample)
SG (2) SG158096A1 (enExample)
TN (1) TNSN07209A1 (enExample)
WO (1) WO2006058316A1 (enExample)
ZA (1) ZA200703328B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007109207A (ru) 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
CA2589265A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
PL1926483T3 (pl) * 2005-09-09 2011-05-31 Novartis Ag Leczenie chorób autoimmunologicznych
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2008248648B2 (en) * 2007-05-04 2012-02-23 Novartis Ag Use of S1P receptor modulator
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
NZ589412A (en) * 2008-05-20 2012-11-30 Kyorin Seiyaku Kk Use of a sphingosine-1-phosphate (S1P) agonist for maintance of induced remission of autoimmune or inflammatory diseases after inital treatment
AU2009273259B2 (en) * 2008-07-23 2013-05-02 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
WO2010020610A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Compounds for the treatment of peripheral neuropathies
MX2011006610A (es) 2008-12-18 2011-06-30 Novartis Ag Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
ES2478842T3 (es) * 2008-12-18 2014-07-23 Novartis Ag Sal clorhidrato del ácido 1-(4-(1-((E)-4-ciclohexil-3-trifluorometil-benziloxiimino)-etil)-2-etil-benzil)-azetidina-3-carboxílico
KR20160064245A (ko) * 2008-12-18 2016-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
AR074826A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
CA2747992C (en) * 2008-12-22 2017-11-07 Novartis Ag Dosage regimen of an s1p receptor agonist
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
AU2010300919A1 (en) 2009-09-29 2012-03-22 Novartis Ag Dosage regimen of an S1P receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
CA2794607A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
PH12013501442B1 (en) 2011-01-07 2018-04-20 Novartis Ag Immunosuppressant formulations
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
HRP20200883T1 (hr) 2012-08-17 2020-09-04 Actelion Pharmaceuticals Ltd. Postupak za pripremanje (2z,5z)-5-(3-kloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međuproizvodi koji se koriste u navedenom postupku
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
JP6401257B2 (ja) 2013-10-11 2018-10-10 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
EA036075B1 (ru) 2014-12-11 2020-09-23 Актелион Фармасьютиклз Лтд Схема дозирования для селективного агониста рецептора s1p1
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008943A1 (fr) * 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
HU224814B1 (en) * 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
USRE39072E1 (en) 1997-04-04 2006-04-18 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
EP1300405B1 (en) 2000-07-13 2007-04-18 Sankyo Company, Limited Amino alcohol derivatives
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
MXPA03008755A (es) 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
WO2002080902A1 (en) * 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
EP1383532B1 (en) * 2001-04-02 2011-05-04 Genentech, Inc. Combination therapy
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JP4476623B2 (ja) * 2001-06-08 2010-06-09 ノバルティス アーゲー インスリン産生細胞移植片拒絶の処置または予防
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
BR0314760A (pt) * 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
CA2589265A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Also Published As

Publication number Publication date
CA2589265A1 (en) 2006-06-01
IL223502A0 (en) 2013-02-03
JP2008521827A (ja) 2008-06-26
CN101068536A (zh) 2007-11-07
KR20070085465A (ko) 2007-08-27
IL183134A0 (en) 2008-04-13
TNSN07209A1 (en) 2008-11-21
EP1819326B1 (en) 2014-07-02
NZ554720A (en) 2011-04-29
NO20121305L (no) 2007-06-22
JP2013129664A (ja) 2013-07-04
SG187468A1 (en) 2013-02-28
NO20072401L (no) 2007-06-22
PL1819326T3 (pl) 2014-12-31
EP2384749A1 (en) 2011-11-09
PT1819326E (pt) 2014-09-25
CN101068536B (zh) 2012-12-05
RU2007124327A (ru) 2009-01-10
EP2359821A1 (en) 2011-08-24
RU2012141951A (ru) 2014-04-10
JP2015061883A (ja) 2015-04-02
US20090275553A1 (en) 2009-11-05
ES2495690T3 (es) 2014-09-17
ZA200703328B (en) 2008-08-27
KR20150028858A (ko) 2015-03-16
EP1819326A1 (en) 2007-08-22
KR20140095109A (ko) 2014-07-31
MA29034B1 (fr) 2007-11-01
US20150087720A1 (en) 2015-03-26
US20120071446A1 (en) 2012-03-22
MX2007006373A (es) 2007-06-20
KR20130041385A (ko) 2013-04-24
NZ590054A (en) 2012-07-27
JP2012107059A (ja) 2012-06-07
CN102600472A (zh) 2012-07-25
WO2006058316A1 (en) 2006-06-01
AU2005309378A1 (en) 2006-06-01
AU2005309378B2 (en) 2010-02-11
BRPI0518674A2 (pt) 2008-12-02
RU2478384C2 (ru) 2013-04-10
HK1109057A1 (en) 2008-05-30

Similar Documents

Publication Publication Date Title
SG158096A1 (en) Dosage regimen of an s1p receptor agonist
TN2011000272A1 (en) Dosage regimen for a s1p agonist
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
DE602005004312D1 (de) Analgistische Darreichungsform, die nicht parenteral oder inhalation dosiert werden können
EP2335734A3 (en) Treatment of pain and other alpha 2 adrenergic-mediated conditions
AU2003275357A1 (en) Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride
EP2044940A3 (en) Methods of treating patients suffering from movement disorders
IL194885A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid
EA200501817A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
MXPA06002726A (es) Metodo para identificar agonistas mejorados no sedantes de alfa-2.
AU2002360462A1 (en) Compositions containing both sedative and non-sedative antihistamines
TNSN05256A1 (en) Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol
MX2007005570A (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
WO2006000567A3 (en) Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
TW200738269A (en) Oral delivery of therapeutic agents using tight junction agonists
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
WO2004034968A3 (en) Combination therapy for controlling appetites
PL2051710T3 (pl) Kompozycje i sposoby leczenia, zmniejszania, polepszania lub łagodzenia chorób tylnego odcinka oka
IL178591A (en) 4– (Amino) –2– (2,6 – Dioxo (3-piperidyl)) - Isoindulin – 1,3 – Dion for the treatment and management of myelodysplastic syndromes
MX2010008220A (es) Metodos que usan compuestos inmunomoduladores para modular nivel de cd59.
IL179896A (en) Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome
WO2003094853A3 (en) Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists